Exploiting intracellular iron and iron-rich compounds to effect tumor cell lysis.
The regimen outlined in this brief paper focuses on therapeutically utilizing iron and iron compounds in transferrin receptor-rich tumor cells in ways that inhibit and lyse same.
Payne
Anthony G
AG
Stem Cell Therapies, San Clemente, CA 92673, USA. dragpayne@yahoo.com
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D037621:Artemisinins / Q000627:therapeutic use; D006801:Humans; D006979:Hyperthermia, Induced; D007501:Iron / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy*; D011990:Receptors, Transferrin / Q000378:metabolism; D012717:Sesquiterpenes / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D037621:Artemisinins; D011990:Receptors, Transferrin; D012717:Sesquiterpenes; C031327:artemisinin; D007501:Iron